Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials
BackgroundChronic coronary syndromes (CCS) is a common clinical condition that increases the risk of cardiovascular events at any time. Tongxinluo capsules (TXL) are widely used in China for treating CCS.ObjectivesTo systematically evaluate the therapeutic effects and safety of adding TXL to Western...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1499585/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556733910056960 |
|---|---|
| author | Shi-Bing Liang Shi-Bing Liang Shi-Bing Liang Yi-Fei Wang Yi-Fei Wang Yi-Fei Wang Zhen-Chao Niu Zhen-Chao Niu Yu-Fei Li Hui-Min Zheng Hui-Min Zheng Jia-Ming Huan Jie Yuan Nicola Robinson Nicola Robinson Jian-Ping Liu Yun-Lun Li Yun-Lun Li Yun-Lun Li |
| author_facet | Shi-Bing Liang Shi-Bing Liang Shi-Bing Liang Yi-Fei Wang Yi-Fei Wang Yi-Fei Wang Zhen-Chao Niu Zhen-Chao Niu Yu-Fei Li Hui-Min Zheng Hui-Min Zheng Jia-Ming Huan Jie Yuan Nicola Robinson Nicola Robinson Jian-Ping Liu Yun-Lun Li Yun-Lun Li Yun-Lun Li |
| author_sort | Shi-Bing Liang |
| collection | DOAJ |
| description | BackgroundChronic coronary syndromes (CCS) is a common clinical condition that increases the risk of cardiovascular events at any time. Tongxinluo capsules (TXL) are widely used in China for treating CCS.ObjectivesTo systematically evaluate the therapeutic effects and safety of adding TXL to Western medical treatment (WM) for CCS.MethodsWe searched PubMed, Cochrane Library, CNKI, VIP, and Wanfang databases up to August 2024 for randomized controlled trials (RCTs) investigating the therapeutic effects and safety of combining TXL with WM compared to WM alone for CCS. Data analyses were conducted using RevMan 5.4 software.ResultsTwenty studies involving 2091 participants were identified. Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. Adding TXL to WM showed a non-significant trend toward reducing myocardial infarction [RR 0.34, 95% CI (0.05, 2.12); NNT = 41] and sudden cardiac death [RR 0.34, 95% CI (0.01, 8.28); NNT = 65]. No increase in adverse events was observed when TXL was added to WM [RR 1.02, 95% CI (0.70, 1.49); NNT = 149].ConclusionsOur review suggests that TXL may offer additional therapeutic benefits for CCS patients and appears to be safe when combined with WM. Further investigations are warranted to confirm the potential impact of adding TXL to WM for CCS.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024499031, PROSPERO (CRD42024499031). |
| format | Article |
| id | doaj-art-95219bc0b58f4cd99a1cf5b3d184f8e3 |
| institution | Kabale University |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-95219bc0b58f4cd99a1cf5b3d184f8e32025-01-07T06:40:41ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-01-011110.3389/fcvm.2024.14995851499585Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trialsShi-Bing Liang0Shi-Bing Liang1Shi-Bing Liang2Yi-Fei Wang3Yi-Fei Wang4Yi-Fei Wang5Zhen-Chao Niu6Zhen-Chao Niu7Yu-Fei Li8Hui-Min Zheng9Hui-Min Zheng10Jia-Ming Huan11Jie Yuan12Nicola Robinson13Nicola Robinson14Jian-Ping Liu15Yun-Lun Li16Yun-Lun Li17Yun-Lun Li18Clinical Study Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, ChinaCentre for Evidence-Based Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaPostdoctoral Research Station, Shandong University of Traditional Chinese Medicine, Jinan, ChinaClinical Study Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, ChinaCentre for Evidence-Based Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaCardiovascular Disease Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, ChinaCentre for Evidence-Based Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaCardiovascular Disease Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, ChinaCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaClinical Study Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, ChinaCentre for Evidence-Based Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaThe First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaCardiovascular Disease Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, ChinaCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaInstitute of Health and Social Care, London South Bank University, London, United KingdomCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, ChinaCardiovascular Disease Center, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, ChinaThe First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, ChinaShandong Engineering Laboratory of Traditional Chinese Medicine Precision Therapy for Cardiovascular Diseases, Shandong University of Traditional Chinese Medicine, Jinan, ChinaBackgroundChronic coronary syndromes (CCS) is a common clinical condition that increases the risk of cardiovascular events at any time. Tongxinluo capsules (TXL) are widely used in China for treating CCS.ObjectivesTo systematically evaluate the therapeutic effects and safety of adding TXL to Western medical treatment (WM) for CCS.MethodsWe searched PubMed, Cochrane Library, CNKI, VIP, and Wanfang databases up to August 2024 for randomized controlled trials (RCTs) investigating the therapeutic effects and safety of combining TXL with WM compared to WM alone for CCS. Data analyses were conducted using RevMan 5.4 software.ResultsTwenty studies involving 2091 participants were identified. Evidence supports the use of TXL plus WM for reducing angina frequency [SMD −2.50, 95% CI (−3.53, −1.48)], improving seattle angina questionnaire scores (P < 0.05), decreasing nitroglycerin dose [SMD −1.63, 95% CI (−2.26, −1.00)], and shortening angina duration [MD −1.50 min/once, 95% CI (−1.98, −1.02)]. Adding TXL to WM showed a non-significant trend toward reducing myocardial infarction [RR 0.34, 95% CI (0.05, 2.12); NNT = 41] and sudden cardiac death [RR 0.34, 95% CI (0.01, 8.28); NNT = 65]. No increase in adverse events was observed when TXL was added to WM [RR 1.02, 95% CI (0.70, 1.49); NNT = 149].ConclusionsOur review suggests that TXL may offer additional therapeutic benefits for CCS patients and appears to be safe when combined with WM. Further investigations are warranted to confirm the potential impact of adding TXL to WM for CCS.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024499031, PROSPERO (CRD42024499031).https://www.frontiersin.org/articles/10.3389/fcvm.2024.1499585/fullchronic coronary syndromescardiovascular diseaseChinese herbal medicinemeta-analysissystematic reviewtongxinluo |
| spellingShingle | Shi-Bing Liang Shi-Bing Liang Shi-Bing Liang Yi-Fei Wang Yi-Fei Wang Yi-Fei Wang Zhen-Chao Niu Zhen-Chao Niu Yu-Fei Li Hui-Min Zheng Hui-Min Zheng Jia-Ming Huan Jie Yuan Nicola Robinson Nicola Robinson Jian-Ping Liu Yun-Lun Li Yun-Lun Li Yun-Lun Li Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials Frontiers in Cardiovascular Medicine chronic coronary syndromes cardiovascular disease Chinese herbal medicine meta-analysis systematic review tongxinluo |
| title | Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials |
| title_full | Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials |
| title_fullStr | Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials |
| title_short | Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials |
| title_sort | chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes a grade assessed systematic review and meta analysis of randomized controlled trials |
| topic | chronic coronary syndromes cardiovascular disease Chinese herbal medicine meta-analysis systematic review tongxinluo |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2024.1499585/full |
| work_keys_str_mv | AT shibingliang chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT shibingliang chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT shibingliang chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yifeiwang chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yifeiwang chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yifeiwang chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT zhenchaoniu chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT zhenchaoniu chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yufeili chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT huiminzheng chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT huiminzheng chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jiaminghuan chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jieyuan chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT nicolarobinson chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT nicolarobinson chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jianpingliu chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yunlunli chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yunlunli chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT yunlunli chinesepatentmedicinetongxinluocapsuleasasupplementtotreatchroniccoronarysyndromesagradeassessedsystematicreviewandmetaanalysisofrandomizedcontrolledtrials |